[HTML][HTML] Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling

ML Capitano, N Mor-Vaknin, AK Saha… - The Journal of …, 2019 - Am Soc Clin Investig
ML Capitano, N Mor-Vaknin, AK Saha, S Cooper, M Legendre, H Guo, R Contreras-Galindo
The Journal of clinical investigation, 2019Am Soc Clin Investig
The nuclear protein DEK is an endogenous DNA-binding chromatin factor regulating
hematopoiesis. DEK is one of only 2 known secreted nuclear chromatin factors, but whether
and how extracellular DEK regulates hematopoiesis is not known. We demonstrated that
extracellular DEK greatly enhanced ex vivo expansion of cytokine-stimulated human and
mouse hematopoietic stem cells (HSCs) and regulated HSC and hematopoietic progenitor
cell (HPC) numbers in vivo and in vitro as determined both phenotypically (by flow …
The nuclear protein DEK is an endogenous DNA-binding chromatin factor regulating hematopoiesis. DEK is one of only 2 known secreted nuclear chromatin factors, but whether and how extracellular DEK regulates hematopoiesis is not known. We demonstrated that extracellular DEK greatly enhanced ex vivo expansion of cytokine-stimulated human and mouse hematopoietic stem cells (HSCs) and regulated HSC and hematopoietic progenitor cell (HPC) numbers in vivo and in vitro as determined both phenotypically (by flow cytometry) and functionally (through transplantation and colony formation assays). Recombinant DEK increased long-term HSC numbers and decreased HPC numbers through a mechanism mediated by the CXC chemokine receptor CXCR2 and heparan sulfate proteoglycans (HSPGs) (as determined utilizing Cxcr2–/– mice, blocking CXCR2 antibodies, and 3 different HSPG inhibitors) that was associated with enhanced phosphorylation of ERK1/2, AKT, and p38 MAPK. To determine whether extracellular DEK required nuclear function to regulate hematopoiesis, we utilized 2 mutant forms of DEK: one that lacked its nuclear translocation signal and one that lacked DNA-binding ability. Both altered HSC and HPC numbers in vivo or in vitro, suggesting the nuclear function of DEK is not required. Thus, DEK acts as a hematopoietic cytokine, with the potential for clinical applicability.
The Journal of Clinical Investigation